HHHBM Bioventures AG
203.00USDD
−5.00−2.40%
At close at Apr 14, 14:26 GMT
USD
No trades
Next report date
July 18
Report period
Q1 2025
EPS estimate
—
Revenue estimate
—
3.32 USD
21.46 M USD
0.00 USD
5.46 M
About HBM Bioventures AG
Sector
Industry
CEO
Andreas Wicki
Website
Headquarters
Zug
Founded
2001
ISIN
CH0012627250
FIGI
BBG003QRPSH8
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−60.00 M
0.00
60.00 M
120.00 M
180.00 M
Revenue
Net income
Net margin %
Revenue
Op expenses
Op income
Int expenses
Non-op income/expenses
Pretax income
Taxes & Other
Net income
−60.00 M
−45.00 M
−30.00 M
−15.00 M
0.00
Revenue
Op expenses
Op income
Expenses & adjustments
Net income
−60.00 M
−45.00 M
−30.00 M
−15.00 M
0.00
No news here
Looks like there's nothing to report right now
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.